enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 2,192,033 shares, an increase of 52.2% from the January 15th total of 1,440,058 shares. Currently, 3.7% of the company’s shares are short sold. Based on an average daily volume of 590,195 shares, the short-interest ratio is currently 3.7 days. Based on an average daily volume of 590,195 shares, the short-interest ratio is currently 3.7 days. Currently, 3.7% of the company’s shares are short sold.

enGene Stock Down 1.6%

Shares of ENGN traded down $0.16 during mid-day trading on Friday, hitting $9.78. The company’s stock had a trading volume of 136,819 shares, compared to its average volume of 452,690. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average is $9.24 and its 200-day moving average is $7.43. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The firm has a market capitalization of $655.16 million, a price-to-earnings ratio of -4.27 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, equities research analysts forecast that enGene will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC purchased a new position in enGene in the second quarter valued at about $36,000. Affinity Asset Advisors LLC bought a new stake in shares of enGene in the 2nd quarter valued at about $280,000. Paloma Partners Management Co bought a new stake in shares of enGene in the 2nd quarter valued at about $38,000. PFS Partners LLC purchased a new position in shares of enGene in the 3rd quarter worth approximately $61,000. Finally, Raymond James Financial Inc. raised its stake in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ENGN shares. Oppenheimer reiterated an “outperform” rating and set a $33.00 price objective (up previously from $30.00) on shares of enGene in a report on Wednesday, November 12th. Jefferies Financial Group assumed coverage on shares of enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 target price on the stock. Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. UBS Group increased their price objective on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. Finally, Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.00.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.